Fotivda 890 Microgram. Fotivda 1340 Microgram 78.2 mg and 77.7 mg Hard capsule
PDF Leaflet Revision Date: 07 February 2022
Clinical Summary
Quick overview from the medicine insert
Indication
First line treatment of advanced renal cell carcinoma.
Dosage (summary)
1340 microgram once daily for 21 days, followed by a 7-day rest.
Special Populations
- Elderly patients
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- St. John's wort
- Strong CYP3A4 inducers
Contraindications
- Hypersensitivity to tivozanib
- Severe hepatic impairment
- Uncontrolled hypertension
- Uncontrolled cardiac failure
Common side effects
- Hypertension
- Dysphonia
- Fatigue
- Diarrhoea
Counselling Points
- Monitor blood pressure regularly
- Avoid pregnancy during treatment
- Do not breastfeed while on Fotivda
Serious warnings
- Hypertension
- Arterial thromboembolic events
- Cardiac failure
- Haemorrhage
Important Disclaimer
The Fotivda 890 Microgram. Fotivda 1340 Microgram 78.2 mg and 77.7 mg Hard capsule professional information leaflet below is the property of Key Oncologics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
